CFP
UTHR icon

Catalyst Financial Partners’s United Therapeutics UTHR Stock Holding History

Catalyst Financial Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$255K Buy
470
+1
+0.2% +$563 0.03% 353
2026
Q1 		$278K Buy
469
+54
+13% +$26.9K 0.03% 305
2025
Q4 		$202K Buy
+415
New +$193K 0.02% 319

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Catalyst Financial Partners's UTHR Position: Q2 2026 in Review

Catalyst Financial Partners increased its United Therapeutics (UTHR) stake by 0.21% in Q2 2026, buying an estimated $563 and bringing the position to 470 shares worth $255K. The position accounts for 0.03% of the portfolio, ranked #353.

Catalyst Financial Partners first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $278K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Catalyst Financial Partners held 470 shares of United Therapeutics worth $255K as of Q2 2026.
  • Catalyst Financial Partners bought 1 United Therapeutics share in Q2 2026, an estimated $563.
  • United Therapeutics made up 0.03% of Catalyst Financial Partners's portfolio in Q2 2026, its #353 holding.
  • Catalyst Financial Partners first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Catalyst Financial Partners's United Therapeutics position peaked at $278K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Catalyst Financial Partners's 13F filing for Q2 2026, filed 30 Jul 2026.